Schmolik, V., et al. (2025) Health services usage in the Austrian osteoarthritis registry show a high level of non-evidence-based therapies. Presented at EULAR 2025; OP0236-HPR.

These data are being presented in three oral presentations at the ongoing European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, in ...

New work presented at the 2025 congress of EULAR – The European Alliance of Associations for Rheumatology – looks at key predictors and outcomes – including a new composite score to help ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

– Both scleroderma patients demonstrated clinically compelling mRSS improvement after discontinuation of all immunomodulators and steroids – – In 18 patients with follow-up of 4 weeks or more, 94% had ...

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress. Cabaletta Bio .

Obesity is a major public health issue for adults, but for an increasing number of patients, its onset begins in childhood. One study found that more than half of children with obesity will remain ...

EULAR - The European Alliance of Associations for Rheumatology - has developed recommendations and clinical practice guidelines for the management of osteoarthritis in the hand, hip, and knee.

Cabaletta Bio Announces New Rese-Cel Safety And Efficacy Data In Patients With Myositis, Lupus And Scleroderma To Be Presented At The EULAR 2025 Congress. Date. 2025-06-11 06:16:13.

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress Provided by GlobeNewswire Jun 11, 2025, 10 ...

- RESET™ clinical trial program enrollment continues to accelerate, with 51 patients now actively enrolled and 24 patients dosed across industry leading US clinical site network as of May 30, 2025 -.